natgillin/translations-raw huggingface dataset:
The rolling mill according to the claim 21, wherein for at least one roll-hydraulic capsule unit of at least one rolling station: 
Valjaonica (20) u skladu s prethodnim patentnim zahtjevom, naznačena time što je za najmanje jednu jedinicu valjak/aktuator najmanje jednog valjaoničkog stana (22):
The inner part of the packaging may comprise an retaining member adapted to be moved between an retaining position wherein it retains the element in a predetermined position and a non-retaining position wherein the element is not retained. 
Unutarnji dio pakiranja može sadržavati član za držanje koji je prilagođen da se može pomicati između položaja za držanje, u kojemu on drži element u unaprijed određenom položaju, i položaja u kojemu nema držanja, u kojemu se element ne drži.
The system according to claim 1, wherein the hydrogel is cross-linked. 
hidrogel je unakrsno povezan; i/ili
Vaccine formulation comprising an adjuvant composition according to claims 11-13. 
Cjepivna formulacija, naznačena time što sadrži adjuvantni pripravak u skladu s patentnim zahtjevima 11-13.
Use of the polypeptide according to one or more of claims 1 to 3 or of the composition of claim 8 for the enzymatic degradation of lignocellulosic biomass, and/or for textiles processing and/or as ingredient in detergents and/or as ingredient in food or feed compositions. 
Upotreba polipeptida u skladu s jednim ili više patentnih zahtjeva 1 do 9 ili pripravka u skladu s patentnim zahtjevom 13, naznačena time, da je namijenjena enzimskoj razgradnji biomase lignoceluloze i/ili za obradu tekstila i/ili kao sastojak u deterdžentima i/ili kao sastojak u hrani ili pripravcima stočne hrane.
In one particular embodiment, the dissolution of cholesterol (or derivatives thereof) in a CF is performed in a reactor at a pressure Pw of approximately 1 to 30 MPa, and a TW of approximately 10 to 70° C. Preferably the approximate temperature of the reactor is between 10 and 50° C. 
Postupak iz patentnog zahtjeva 7 ili 8, pri čemu se rastvaranje kolesterola, ili njegovih derivata, u CF izvodi u reaktoru pod odgovarajućim pritiskom od 1 do 30 MPa i približnoj temperaturi od oko 10 do 70 *C, preporučljivo između 10 150 *C. 10.
Ra and Rb together form a 5-7 member cyclic structure fused directly to the indolo[2,3-a]carbazole nucleus structure, containing 0, 1 or 2 heteroatoms and optionally containing a carbonyl group and the cyclic structure being unsubstituted or substituted by at least one substituent group selected from a carbonyl group or W1 or W2 and wherein if a heteroatom member of the cyclic structure is nitrogen, the nitrogen is substituted by the residue R3; and wherein Rc and Rd are 
R* i R" zajedno formiraju 5-7 -članu cikličnu strukturu fuzioniranu direktno za strukturu jezgra indolo[2,3-a] karbazola, koja sadrži 0, 1 ili 2 heteroatoma i koja izborno sadrži karbonil grupu i cikličnu strukturu koja je nesupstituirana ili supstituirana sa najmanje jednom supstituirajućom grupom izabranom od karbonil grupe ili W' ili W? i pri čemu ako je heteroatom član ciklične strukture dušik, dušik je supstituiran sa ostatkom R3; i gdje, R"i R" su
A preferred formulation is one obtained from 0.9% sodium chloride or other suitable infusion vehicle, 250 µg of ET-743 with 250 mg of mannitol, 34 mg of manopotassium phosphate, and phosphoric acid to adjust the pH. 
Poželjni oblik je onaj dobiven iz 0.9% natrijklorida ili drugog pogodnog infuzijskog nosača, 250 ug ET-743 s 250 mg manitola, 34 mg monokalij fosfata i fosforne kiseline za podešavanje pH vrijednosti.
The storage system according to claim 1, wherein the bin lift device is further arranged to receive a storage bin from the second vehicle at the top level of the second grid structure and to convey the storage bin in a vertical direction to the top level of the first grid structure. 
Sustav za skladištenje sukladno jednom od prethodnih patentnih zahtjeva sastavljenih od najmanje jednog inter-rešetkastog dizala postavljenog radi prijema kontejnera za skladištenje s vozila na najvišoj razini (20) prve strukture rešetke i da okomito prenosi kontejner za skladištenje do najviše razine (22) druge strukture rešetke.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) fluopyram. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fluopiram.
Sulfur dioxide 0.45-0.55 
0.45 - 0.55 organska kiselina
• mixing the crude palm fruit oil product with an aqueous liquid having an alkaline pH of more than 8 to produce an oil-and-water mixture; and 
miješanja sirovog ulja kao proizvoda palminog ploda s vodenom tekućinom alkalnog pH višeg od 8 kako bi se dobilo smjesu ulje-i-voda; i *
twice daily for 7 days followed by 7 days drug-free period) or vehicle followed by acute treatment with Isomer A, risperidone or vehicle. 
dva puta dnevno tijekom 7 dana nakon čega je slijedilo sedmodnevno razdoblje bez lijeka) ili nakon tretiranja s podlogom, nakon čega je slijedio akutni tretman s Izomerom A, risperidonom ili podlogom.
According to another aspect of the present invention, there is provided a floating structure with a fuel gas tank storing a gaseous fuel used as fuel while floating at sea. 
Plutajuća struktura sa spremnikom za plinovito gorivo (104) prema zahtjevu 1, naznačena time da blokirajući element je nepropusna pregrada koja blokira toplinu i plin koji nastaje tijekom požara.
The method of claim 5 or 6, wherein said method converts MRD positive ALL into an MRD negative status. The method of any of claims 5 to 7, wherein MRD is measured with quantitative detection of at least one of the cytogenetic abnormalities or rearrangements selected from the group consisting of: 
Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 4 ili 5, naznačen time što se MRD mjeri kvantitativnim opažanjem najmanje jedne od citogenetičkih abnormalnosti ili pregradnji, koje se bira iz skupine koju čine: 4(12;21)[TEL-AMLI];
After reflux at 95° C. overnight, the reaction mixture was cooled to ambient temperature and the volatiles were removed. 
Nakon rcfluksiranja preko noći na 95 "C rcakcijsku smjesu sc ohladi na temperaturu okoliša, a hlapive tvari ukloni.
The composition according to claim 5, said deoxygenating producing a deoxygenated hemoglobin molecule, which is (i) bound to neither oxygen nor carbon monoxide; or (ii) bound to carbon monoxide. 
Pripravak sukladno zahtjevu 5, spomenuta deoksigenacija stvara deoksigeniranu molekulu hemoglobina, koja (i) nije vezana ni za kisik, ni za ugljični monoksid; ili (ii) je vezan za ugljični monoksid.
The process according to claim 10, characterized in that the organic dispersing agent comprises an acrylic polymer, a vinylic polymer, an acrylic and/or a vinylic copolymer and the inorganic dispersing agent comprises mono-, di- and/or trisodium orthophosphate, sodium tripolyphosphate and/or sodium polyphosphate. 
Postupak prema zahtjevu 10, naznačen time što organsko disperzno sredstvo obuhvaća akrilni polimer, vinilni polimer, akrilni i/ili vinilni kopolimer i anorgansko disperzno sredstvo koje obuhvaća mono-, di i/ili trinatrijev ortofosfat, natrijev tripolifosfat i/ili natrijev polifosfat.
In general, the “pro-drug” approach is utilized to facilitate oral absorption. 
Općenito, "pro-lijekovi" se koriste da bi se olakšala oralna apsorpcija.
The immunogenic composition of embodiment 49 or 50 wherein the at least two further bacterial saccharide conjugates comprise N. meningitidis serogroup C capsular polysaccharide (MenC) conjugate. 
Imunogeni pripravak u skladu s patentnim zahtjevom 3, naznačen time što najmanje dva dodatna konjugata bakterijskih saharida sadrže saharid iz kapsule bakterije N. meningitidis seroskupina € (MenC).
In particular, the expression vector of the invention may be used in gene therapy. 
Ekspresijski vektor u skladu s patentnim zahtjevom 10 za uporabu u genskoj terapiji.
Statistical significance between experimental groups is assessed using a two-sided student's t-test. 
Statistički značaj između eksperimentalnih skupina procijenjen pomoću dvostranog Studentovog t-ispitivanja.
Process according to claim 1, wherein the cylinder oil produced comprises at least 1% by weight used oil, based on the total amount of cylinder oil produced and/or at least 1% by weight of fresh cylinder oil, based on the total amount of cylinder oil produced. 
Postupak prema zahtjevu 1, naznačen time da proizvedeno cilindarsko ulje sadrži najmanje 1 % težinski rabljenog ulja, u odnosu na ukupnu količinu proizvedenog cilindarskog ulja i/ili najmanje 1 % težinski svježeg cilindarskog ulja, u odnosu na ukupnu količinu proizvedenog cilindarskog ulja.
The construct for the use of any one of claims 7 to 9, wherein the two initial doses are administered for 2, 3, 4, 5, 6, or 7 days or even longer. 
Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 17, naznačen time što se dvije početne doze primjenjuje 2, 3, 4, 5, 6 ili 7 dana ili čak 1 dulje.
The Schiff base-containing concentrate was hydrqgenated for 2 hours over 5.0 g. of 10% Pd/C catalyst at atmospheric pressure and room temperature. 
Koncentrat koji sadrži Å if-ovu bazu hidrogenzira se 2 sata preko 5.0 g. 10% Pd/C katalizatora na atmosferskom tlaku i na sobnoj temperaturi.
An article of manufacture according to claim 37, wherein the packaging material comprises a container for housing the multiple doses of the pharmaceutical composition. 
Proizvodni artikl prema patentnom zahtjevu 40, naznačen time što materijal za pakovanje sadrži kontejner za smještaj višestrukih doza farmaceutske kompozicije.
X is selected from the group consisting of C, N, O, and S; m and n, which may be the same or different, are each an integer of 0, 1, 2, or 3; 
X se bira iz skupine koja sadrži C, N, 0, i S; tje broj od 0, 1, 2, ili 3;
Illustrative fibrotic diseases include but are not limited to pulmonary fibrosis, such as idiopathic pulmonary fibrosis and cystic fibrosis, renal fibrosis, including tubular atrophy and interstitial fibrosis, liver fibrosis, liver cirrhosis, primary sclerosing cholangitis, primary biliary cirrhosis, endomyocardial fibrosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, Crohn's disease, keloid, myocardial infarction, scleroderma, systemic sclerosis and arthrofibrosis. 
Antitijelo za upotrebu prema patentnom zahtjevu 11 naznačeno time da je fibrozna bolest odabrana iz skupine koja se sastoji od fibroze pluća kao što je idiopatska fibroza pluća i cistična fibroza, fibroza bubrega, ciroza jetre, endomiokardijalna fibroza, medijastinalna fibroza, mijelofibroza, retroperitonealna fibroza, progresivna masivna fibroza, nefrogena sistemska fibroza, Chron-ova bolest, keloid, infarkt miokarda, sklerodermija i artrofibroza.
A peptide as claimed in claim 7, wherein the carrier comprises 5-CNAC, SNAD, or SNAC. 
Peptid, sukladno patentnom zahtjevu 6, naznačen time da nosač 5-CNAC, SNAD ili SNAC.
Particularly preferred membranes comprise, as materials for the separation-active layer or as a material for the complete membrane, a polyimide of the general formula 
Postupak prema zahtjevu 9, naznačen time da materijal koji se koristi za separacijski aktivni sloj membrana je poliimid s općom formulom o o
represents a hydrogen atom, a fluoro atom, a chloro atom or a bromo atom; 
R* predstavlja vodikov atom, fluorov atom, klorov atom, ili bromov atom;
an entropy decoder (520, 1510) that performs entropy-decoding to obtain quantized transformation coefficients of at least one transformation unit (870) in a coding unit (810); 
određivanje najmanje jedne transformacijske jedinice koja je podijeljena iz jedinice kodiranja korištenjem informacija o transformacijskoj jedinici, pri čemu se informacija o transformacijskoj jedinici raščlanjuje iz toka bitova;
Upon cooling, crystals formed which were collected by filtration, washed with a water:isopropanol (1:1) solution, and dried. 
Nakon hlađenja su nastali kristali koji su skupljeni filtracijom, isprani otopinom voda:izopropanol (1:1), i osušeni.
each R22 is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; 
svaki R2 predstavlja nezavisno ostatak amino kiseline nastao nakon uklanjanja hidroksilne skupine iz karboksilne skupine;
coating the particulate polylactic acid obtained in step b); 
oblaganja partikulirane polimliječne kiseline dobivene u koraku b)
T represents one of the 5-membered heteroaromatics T1-T7 listed below, where the bond to the pyrazole head group is marked with an asterisk, 
T predstavlja jedan od 5-članih heteroaromatika T1-T7 koji su navedeni ispod, gdje je veza na glavnu skupinu pirazola označena sa zvjezdicom,
The first pilot signal includes the cyclic prefix obtained by frequency-shifting the first portion of the valid portion thereof and the cyclic suffix obtained by frequency-shifting the second portion of the valid portion thereof The timing offset and the frequency offset may be calculated using the first pilot signal as follows The received signal is delayed (S311) For example, the delay portion may be the valid portion of the first pilot signal or 1/2 of the valid portion. 
Od primljenog signala prvi pilni signal koli uključuše ciklišni prefiks dobiven pomoću pomicanja frakvencije prvog udjela korisnog udjela i oiklićni sušike dobiven pomoću pomitanja frekvencija drugog udjela korisnog udiela je utvrđen i okvir signafa koli uključuje PLP je demoduliran pomoću shema OFOM korištenjem informacija poslavjenim u prvom pilot signalu. kdentificirani okvir signala ja analiziran, Servis može bili dobiven od PLP anaiiziranog okvira signala. "SZ10
The dihydrate according to claim 1 or 2 which has characteristic peaks at 3509 cm-1, 2934 cm-1, 2812 cm-1, 1651 cm-1, 1626 cm-1, 1447 cm-1, 1223 cm-1, and 839 cm-1 in an infrared absorption spectrum as measured by a potassium bromide tablet method. 
Dihidrat prema zahtjevu 1 ili 2 naznačen time da ima karakteristične vrhove kod 3509 cm'!, 2934 cm'!, 2812 cm, 1651 cm", 1626 cm", 1447 cm", 1223 cm", i 839 cm"! u infracrvenom apsorpcijskom spektru mjereno pomoću postupka s tabletom kalijevog bromida.
The composition of any one of claims 2-4, wherein the composition is formulated for oral, sublingual, transdermal, suppository, parenteral, intravenous, or intrathecal administration. 
Pripravak sukladno zahtjevu 1, naznačeno time, da je pripravak formuliran za oralno, sublingvalno, transdermalno, intratekalno ili davanje supozitorija.
The mouse of claim 1, wherein the humanized PD-1 polypeptide is translated in a cell of the mouse with a mouse signal peptide. 
Miš u skladu s patentnim zahtjevom 1, naznačen time što humanizirani polipeptid PD-1: se translatira u mišjoj stanici s mišjim signalnim peptidom; ili
Other isoforms of Ig molecules are also suitable for the generation of fusion proteins according to the present invention, such as isoforms IgG2 or IgG4, or other Ig classes, like IgM or IgA, for example. 
Drugi izooblici molekula Ig također su pogodni za razvijanje fuzijskih proteina iz ovoga izuma poput izooblici IgG, ili IgG, ili drugih Ig klasa kao IgM ili IgA.
etherifying an intermediate (V) with a quinoline of formula (VI) as outlined in the following reaction scheme: 
(d) esterifikaciju intermedijera (V) sa kinolinom formule (VI) kako je navedeno u slijedećoj reakcijskoj shemi:
The antibody of claim 3, wherein the heavy chain comprises a VH domain comprising or consisting of the amino acid sequence set forth in SEQ ID NO:30 and the light chain comprises a VL domain comprising or consisting of the amino acid sequence set forth in SEQ ID NO:29. 
Protutijelo u skladu s patentnim zahtjevom 3, naznačeno time što teški lanac sadrži VH domenu koja sadrži ili koju čini aminokiselinski slijed iznijet u SEQ ID NO:30 i laki lanac sadrži VL domenu koja sadrži ili koju čini aminokiselinski slijed iznijet u SEQ ID NO:29.
• when RCG1 represents a O-alkyl hydroxylamine function or a Pictet-Spengler reaction substrate, RCG2 represents an aldehyde or ketone function. 
* kada RCGI predstavlja O-alkil hidroksilaminsku funkciju ili Pictet-Spengler reakcijski supstrat, RCG2 predstavlja aldehidnu ili ketonsku funkciju.
The aqueous solution is acidified to pH 3-4, and extracted with EtOAc. 
Vodenu otopinu se zakiseli na pH 3-4 i ekstrahira s EROAc.
A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, as an active ingredient in association with a pharmaceutically acceptable carrier, diluent or excipient. 
Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo koji od patentnih zahtjeva 1 do 14 kao aktivni sastojak u smjesi s farmaceutski prihvatljivom podlogom, razrjeđivačem ili pomoćnom tvari.
Process according to claim 6, characterized in that it is an inhalable aerosol with or without propellant. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time, da je aerosol za inhaliranjo sa ili bez potisnog plina.
In one embodiment, the human portion of the chimeric polypeptide is derived from a human HLA class II protein selected from the group consisting of HLA-DR, HLA-DQ, and HLA-DP, e.g., the human portion is derived from HLA-DR4 protein. 
1 genski lanac HLA-DP a i/ili ljudski dio kimernog MHC II f polipeptida čovjeka/glodavca kodira ljudski genski lanac klase HLA II a koji je odabran iz grupe koja sadrži genski lanac HLA-DR (8, genski lanac HLA-DQ fi i genski lanac HLA-DP (.
The monoclonal antibody or a functional fragment of the monoclonal antibody according to any one of claims 1 to 7, characterized in that the antibody is an antibody produced by hybridoma FERM BP-10999 (#32A1) or hybridoma FERM BP-11000(#41B1). 
Monoklonsko antitijelo ili njegov funkcionalni fragment, sukladno sa bilo kojim od zahtjeva 1-7, karakteriziranih time da je antitijelo antitijelo proizvedeno od hibridoma stanica FERM BP-10999 (#32A1) ili hibridoma stanica FERM BP-11000(#41B1).
A pharmaceutical tablet especially in accordance with the preceding items having a penetration depth to crack distance of at least 1.0 mm, preferably 1.2 mm, more preferably 1.4 mm, and even more preferably 1.6 mm, when subjected to an indentation test. 
Farmaceutska tableta prema bilo kojem od prethodnih zahtjeva naznačena time da ima dubinu prodiranja s razmakom pukotine od najmanje 1.0 mm, poželjno 1.2 mm, poželjnije 1.4 mm, te još poželjnije 1.6 mm, kada je podvrgnuta indentacijskom testu.
Method for treating water at low cost, wherein the method purifies the water and eliminates suspended solids in the water by filtering a small fraction of the total volume of water, the method comprising: 
Uređaj obuhvaća sustav za izvođenje industrijskog postupka i sustav s niskim troškovima koji uklanja otopljene čvrste čestice filtriranjem male frakcije ukupnog volumena vode, uređaj obuhvaća:
The use of a composition comprising a dried, nonviable selenium-enriched yeast wherein the total selenium content of said yeast comprises two percent or less inorganic selenium in the manufacture of a medicament, wherein the medicament is formulated for administration to a subject under conditions such that the expression of a gene selected from the group consisting of Lhx8 and TGFB-2 is enhanced in said subject for the treatment of neurodegenerative disease selected from amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, multiple sclerosis, spinocerebellar ataxia, Friedreich's ataxia, and myotonic dystrophy. 
Pripravak koji se koristi u proizvodnji lijeka sadrži suhi, neživi kvasac obogaćen selenom, naznačen time da u ukupnom sadržaju selena ima dva posto ili manje neorganskog selena, pri čemu je lijek formuliran za primjenu u subjektu pod uvjetom da se izražavanje komplement gena smanjuje u moždanoj kori tog subjekta u svrhu liječenja ili prevencije Alzheimerove bolesti.
The CH2Cl2 layer was decanted from the insoluble oil. 
CH2CI, sloj je odliven iz netopljivog ulja.
A method as in claim 9 wherein the disorder is a neuropathic pain, chronic pain and/or acute pain. 
Spoj iz bilo kojeg od patentnih zahtjeva 1 do 10 za upotrebu kao lijek za liječenje neuropatske boli, kronične boli i/ili akutne boli.
The peptide for use according to Claim 1, wherein said peptide includes non-peptide bonds. 
Peptid u skladu s patentnim zahtjevom 1, pri čemu navedeni peptid uključuje nepeptidne veze.
Alternatively compounds of formula (I) wherein Y represents a carbonyl group may be prepared by oxydation of a compound of formula (I) wherein Y represents a methylene group substituted by a hydroxyl group according to well known methods to one skilled in the art. 
Alternativno se spojeve formule (1), gdje Y predstavlja karbonilnu skupinu, može dobiti oksidacijom spoja formule (I), gdje Y predstavlja metilensku skupinu, supstituiranu s hidroksilnom skupinom, postupcima dobro poznatim stručnjaku.
A peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 100, 80, and 101 in which 1 or 2 amino acids are substituted, wherein said peptide induces a cytotoxic T cell specific to a cell expressing ETC2. 
Peptid od manje od 15 aminokiselina koji može inducirati citotoksičnu T-stanicu, naznačen time što navedeni peptid ima aminokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO:41, 44, 46, 48 i 78, u kojima je jedna aminokiselina zamijenjena, gdje navedeni peptid inducira citotoksičnu T-stanicu specifičnu za stanicu koja eksprimira EphA4.
It is further demonstrated that on comparison of dissolution of tablets comprising crystalline versus micronized nebivolol, the dissolution rate of the tablet comprising crystalline nebivolol (Example 6 of EP 744946) is less than 50% after 45 minutes. 
Nadalje je pokazano da u usporedbi tableta za otapanje koje sadrže kristalni nasuprot mikroniziranom nebivololu, stopa otapanja tableta koje sadrže kristalni nebivolol (Primjer 6 EP 744946) manja je od 50 % nakon 45 minuta.
As the present composition is suitably used to reduce the allergic reaction in an infant and/or toddler, the protein of the infant nutrition is preferably selected from the group consisting of hydrolysed milk protein (e.g. hydrolysed casein and/or hydrolysed whey protein), hydrolysed vegetable protein and/or amino acids. The use of these proteins further reduces the allergic reactions of the infant and/or toddler and/or increases protein absorption. 
Hrana u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je nevijabilna B. breve odabrana od nevijabilnog soja B. breve M-16Y i soja B. breve I-2219. Uporaba hrane za dojenčad i/ili dijete prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što je za proizvodnju pripravka za osiguravanje prehrane za dojenčad i/ili dijete.
Manufacture of beacon 1 is completed by applying cover plate 22 . 
Izrada balize 1 se dovršava nanošenjem pokrovne ploče 22,
wherein R1, R2 and R4 are as in claim 1; and R3 is halo, substituted or unsubstituted C1-C6 alkyl or cycloalkyl; or a pharmaceutically acceptable salt, tautomer or isotopic variant thereof. 
R!', RŽiR', R' su kao u zahtjevu 1; i R> je halo, supstituiran ili nesupstituiran C,-Cg alkil ili cikloalkil; ili farmaceutski prihvatljiva sol, solvat, tautomer ili njihova izotopna varijanta.
In some embodiments the viscous material further comprises isophthalic acid and at least one polycondensation catalyst; and the invention method further comprises transesterifying the RPET and reacting the added ingredients TPA, IPA, DEG, polycondensation catalyst, and MEG at a temperature of from 250 °C to 270 °C in such a way so as to produce the mixture comprising PET and ethylene terephthalate oligomers in the first container. 
Postupak prema zahtjevu 9, naznačen time, da postupak nadalje obuhvaća transesterifikaciju recikliranog polietilen tereftalata i reakciju dodanih sastojaka tereftalne kiseline i monoetilen glikola na temperaturi od 250 do 270 stupnjeva Celzija na način da se dobiju oligomeri etilen tereftalata u prvom spremniku.